GLP-1 Weight Loss in Singapore

What GLP-1 actually is

GLP-1 — short for glucagon-like peptide-1 — is a hormone your own body makes. It is released by cells in the gut after you eat, and it belongs to a family of signals called incretins that help the body coordinate digestion and blood sugar.

After a meal, GLP-1 does three useful things. It prompts the pancreas to release insulin so glucose can be used for energy. It reins in a second hormone, glucagon, that would otherwise raise blood sugar. And — the part most relevant to weight — it slows the stomach's emptying and sends a "you've had enough" signal to the brain.

In short, GLP-1 is part of your body's natural fullness and blood-sugar machinery. Medicines that act on this pathway are essentially turning up a signal that already exists.

How the mechanism works for weight loss

Medicines in this class act on the same receptor your own GLP-1 does, and for longer. That has a practical consequence: hunger is quieter, and food occupies less mental space. For most patients, eating less stops being something you have to force and becomes something you can sustain.

The effect is mostly appetite-driven rather than a change to your metabolism. Because the stomach empties more slowly, you feel fuller sooner and for longer, and the drive to snack between meals tends to fall away. That is why the medicine is described as supporting weight loss rather than causing it on its own.

This is also why the effect is not permanent by itself. If treatment stops and nothing else has changed, appetite signalling returns to where it was — a point the maintenance section below returns to.

What the clinical evidence shows

In large randomised controlled trials, GLP-1 receptor agonists used for weight management produced average weight loss in the region of 10% to 20% of body weight over roughly a year, when combined with reduced food intake and increased activity. For a person weighing 90 kg, that is roughly 9–18 kg on average.

Two honest caveats sit alongside those numbers. First, they are averages — some people lose more, some less, and a minority lose little. Second, the weight loss came in programmes that also changed what and how much people ate, not from the medicine acting in isolation.

Alongside the weight itself, trials commonly report improvements in weight-related measures such as blood pressure, blood-sugar control and cholesterol. The pattern matters because it reflects what patients most want: not a smaller number on the scale alone, but a lower burden of the conditions that travel with excess weight.

The evidence also supports the framing we use in clinic: obesity behaves as a chronic condition, not a one-off problem with a one-off fix. The medicines are a powerful tool, but they are a tool you use within a longer plan.

Who it may suit

Whether this class of treatment is appropriate is always decided at a clinical assessment, not by self-selection. As a guide, weight-management medicines are generally considered when a person's body-mass index (BMI) is in the obesity range, or in the overweight range together with a weight-related health problem.

Because health risk rises at a lower BMI in Asian populations, Singapore follows the lower cut-offs: a BMI of 27.5 or above is considered obesity, and 23.0–27.4 is considered overweight (WHO obesity classification). Weight-related conditions that shift the balance toward medical treatment include type 2 diabetes, high blood pressure, obstructive sleep apnoea and joint problems.

It is also usually considered after — not instead of — a genuine attempt with nutrition and activity. If lifestyle changes alone have not achieved or sustained enough, a doctor may discuss whether a medicine in this class has a role.

Who it is not for

This class of treatment is not for everyone, and some people should not take it at all. The main exclusions are:

• Pregnancy, trying to conceive, or breastfeeding. Weight-management medicines are not used in this context, and treatment is usually paused.
• A personal or family history of medullary thyroid carcinoma (a specific thyroid cancer), or the inherited condition MEN2.
• A history of pancreatitis (inflammation of the pancreas).
• Significant stomach or bowel disease, including severe gastroparesis (delayed stomach emptying) or inflammatory bowel disease.
• Active gallbladder disease, or a history of gallstone complications — these need careful discussion first.

Your doctor screens for these and other conditions before starting, and reviews whether any of your existing medicines interact. This is one reason treatment is never dispensed without a consultation.

This class of medicine is also not a shortcut, not a replacement for nutrition and activity, and not a treatment to source online. It is a prescription medicine used within a supervised programme, or not at all.

How treatment is given and what to expect

Most medicines in this class are given as an injection under the skin, commonly once a week. Your doctor or nurse shows you how to give it yourself at home — most patients find it straightforward after the first demonstration.

Treatment starts at a low dose and is increased gradually, usually over several weeks. This slow escalation is deliberate: it is what keeps the common gastrointestinal side effects manageable while your body adapts.

Expect regular reviews rather than a single visit. At each follow-up the clinic checks your weight, measurements and any relevant blood results, asks how you are tolerating the dose, and decides whether to adjust. The typical course is measured in months, not a single prescription — consistent with treating obesity as a chronic condition.

Why medical supervision matters

• Assessment first. Your history, examination and current medicines determine whether this class is appropriate at all — and what to watch for.
• Dose escalation. Starting low and increasing slowly is what keeps side effects manageable — a schedule your doctor sets against your tolerance.
• Monitoring. Weight, measurements and relevant blood results are reviewed, so problems are caught early rather than late.
• Maintenance planning. The exit from treatment needs a plan, made before it is needed — not improvised after regain.
• Authenticity. Medicines dispensed through a registered clinic and licensed pharmacy — not bought online, where products may be counterfeit or unsafe.

Side effects and how they are managed

The most common side effects are gastrointestinal: nausea, reflux, constipation or loose stools. They are usually strongest in the days after a dose increase and settle as the body adapts. Eating smaller portions, avoiding very fatty meals, and staying hydrated all help, as does the gradual dose schedule itself.

Less common effects can be more serious and should be reported promptly: severe or persistent abdominal pain (which can signal pancreatitis), persistent vomiting, signs of a gallbladder problem, or unusual fatigue. Because of a signal seen in animal studies, doctors also advise patients to report any new neck lump or hoarseness.

Effects that are severe, persistent or unexpected should be reported to the clinic rather than tolerated. Dose adjustment is a normal part of treatment, not a failure of it.

This page describes a class of treatment for patient education. In line with Singapore's Health Products (Advertisement of Specified Health Products) Regulations, it does not name, price or promote any prescription medicine. Treatment is discussed only in consultation.

Maintenance and life after treatment

The single most common question after "does it work" is "what happens when I stop?" The honest answer: weight regain after stopping is common, because appetite signalling returns to its previous state. This is not a failure of willpower — it is the underlying biology reasserting itself.

That is why the programme treats maintenance as its own phase. Before treatment is tapered, the clinic works with you on the nutrition, activity and follow-up habits that will carry the result forward. For some people, maintenance involves a lower maintenance dose; for others, a structured transition off the medicine. The plan is made with you, and made before it is needed.

GLP-1 in Singapore: regulation and safety

In Singapore, medicines in this class are prescription-only, regulated by the Health Sciences Authority (HSA). They cannot lawfully be advertised to the public, and they are supplied only through registered clinics and licensed pharmacies after a doctor's assessment.

That regulation exists for good reason. These are powerful medicines with real contraindications and side effects, and they are not interchangeable between patients. A medicine bought online, without a prescription, may be counterfeit, incorrectly dosed, or simply not right for your history.

If you are considering this treatment, the safe route is the one the regulations intend: a consultation with a registered doctor, a proper assessment, and ongoing supervision. That is the route this clinic follows.

Sources and further reading

• Health Sciences Authority (HSA) — regulation of health products in Singapore
• Ministry of Health (MOH) Singapore — national obesity and weight-management guidance
• World Health Organization — obesity and overweight fact sheet (including Asian BMI cut-offs)
• Health Promotion Board Singapore — healthy weight resources
• NIH (NIDDK) — weight management and related conditions